Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543846 | 0.78 | BCHE (0.40) | BCHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1544238 | 0.76 | KMT2A (0.41) | RAB9ABCHEMEN1HPGDKMT2A | |
| SCHEMBL1543493 | 0.75 | CYP3A4 (0.42) | TGFBR1RAB9ADUSP3PTPN11BCHE | |
| SCHEMBL1543937 | 0.69 | EPHX2 (0.38) | TGFBR1CSF1RRAB9AMEN1KMT2A | |
| SCHEMBL1545215 | 0.67 | KMT2A (0.42) | RAB9AMEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL1544865 | 0.65 | CYP3A4 (0.40) | MEN1KMT2A | |
| SCHEMBL1544638 | 0.63 | GRM5 (0.33) | TGFBR1CSF1RMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1544806 | 0.61 | MEN1 (0.51) | RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1544252 | 0.61 | TSHR (0.43) | RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6850890 | 0.61 | NPC1 (0.54) | RAB9AMEN1KMT2ASMN1; SMN2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | GCGR 277/4885TGFBR1 2123/4885CSF1R 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.